-
Uncategorized1 month agoFrom Discovery to GMP: Building Scalable Cell Therapy Manufacturing
Read Now Over the past decade, our industry has witnessed the promise of cell and gene therapies. Patients with rare diseases or hard-to-treat diagnoses now have...
-
Uncategorized1 month agoSTAT+: Oregon hospitals won’t outsource to national physician chain after all
After a tidal wave of blowback that culminated in a lawsuit, a nonprofit health system has reversed course in its plan to replace its Oregon emergency...
-
Uncategorized1 month agoMicroproteins and Peptideins Expand Boundaries of the Human Proteome
A research team led by scientists at the Princess Máxima Center for Pediatric Oncology, the University of Michigan Medical School, EMBL European Bioinformatics Institute, and the...
-
Uncategorized1 month agoTrump administration’s drug strategy is at odds with recent actions on funding, policy
The White House’s new strategy for addressing the nation’s drug crisis calls for a number of consensus public health measures: the overdose-reversal medication naloxone, medication-assisted treatment,...
-
Uncategorized1 month ago
Amgen, AbbVie say IRA negotiations impacted Q1 sales
At least two drugmakers say they’re feeling the impact of the Inflation Reduction Act, after the first drug prices negotiated under the law took effect in...
-
Uncategorized1 month ago
Lilly plans new $4.5B manufacturing investment in Indiana
Eli Lilly is committing to its roots, allocating $4.5 billion for new manufacturing investments across Indiana as drugmakers pledge more US projects. The world’s largest pharma...
-
Uncategorized1 month agoSTAT+: Administration report on most favored nation drug pricing raises new details — and questions
WASHINGTON — The Trump administration on Tuesday released the most detailed look to date at its drug pricing policy and its purported impact, claiming huge future...
-
Uncategorized1 month agoSTAT+: Sanofi asks to pull diabetes drug out of FDA voucher program after political appointee interfered with review
WASHINGTON — Sanofi has asked the Food and Drug Administration to pull its type 1 diabetes drug, teplizumab, out of Commissioner Marty Makary’s new speedy drug...
-
Uncategorized1 month agoBayer to buy Perfuse for up to $2.45B, bolstering eye drug pipeline
Centered around a glaucoma therapy in mid-stage testing, the deal is Bayer’s first drug company acquisition in several years and potentially its largest since it purchased...
-
Uncategorized1 month ago
Heavy-Chain BsAbs More Manufacturable than Light-Chains
Bispecific antibodies (BsAb) were first approved in 2014. Since then, a total of 19 have been approved globally, and approximately 250 BsAbs are being developed by...
